Jaume Aguero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1156998/publications.pdf

Version: 2024-02-01

103	3,663	29 h-index	58
papers	citations		g-index
111	111	111	5621
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Endobronchial Aerosolized AAV1.SERCA2a Gene Therapy in a Pulmonary Hypertension Pig Model: Addressing the Lung Delivery Bottleneck. Human Gene Therapy, 2022, 33, 550-559.	1.4	4
2	A Critical Appraisal of Absolute Left Ventricular Dimension Thresholds for Intervention in Primary Mitral Regurgitation from a Worldwide Population Perspective. Journal of the American Society of Echocardiography, 2021, 34, 205-206.	1.2	1
3	Variations in T2-Mapping-Assessed Area at Risk After Experimental Ischemia/Reperfusion. Journal of Cardiovascular Translational Research, 2021, 14, 1040-1042.	1.1	2
4	Proceduralâ€related coronary atrial branch occlusion during primary percutaneous coronary intervention for STâ€segment elevation myocardial infarction and atrial arrhythmias at followâ€up. Catheterization and Cardiovascular Interventions, 2020, 95, 686-693.	0.7	3
5	Quantitative Transthoracic Echocardiography of the Response to Dobutamine in Cardiac Surgery Patients With Low Cardiac Output Syndrome. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 87-96.	0.6	7
6	R2 prime (R2′) magnetic resonance imaging for post-myocardial infarction intramyocardial haemorrhage quantification. European Heart Journal Cardiovascular Imaging, 2020, 21, 1031-1038.	0.5	4
7	Echocardiographic Left Ventricular Mass Estimation: Two-Dimensional Area-Length Method is Superior to M-Mode Linear Method in Swine Models of Cardiac Diseases. Journal of Cardiovascular Translational Research, 2020, 13, 648-658.	1.1	4
8	Changes in Adrenoceptor and GRK Expression in Patients With Chronic Pulmonary Regurgitation. Revista Espanola De Cardiologia (English Ed), 2019, 72, 569-576.	0.4	1
9	\hat{l}^2 2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation. Frontiers in Pharmacology, 2019, 10, 93.	1.6	2
10	Serial Magnetic Resonance Imaging toÂldentify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology, 2019, 73, 779-791.	1,2	174
11	Sequential Bone-Marrow Cell Delivery of VEGFA/S1P Improves Vascularization and Limits Adverse Cardiac Remodeling After Myocardial Infarction in Mice. Human Gene Therapy, 2019, 30, 893-905.	1.4	8
12	Left Ventricular Unloading Using an Impella CP Improves Coronary Flow and Infarct Zone Perfusion in Ischemic Heart Failure. Journal of the American Heart Association, 2018, 7, .	1.6	65
13	Deciphering microvascular changes after myocardial infarction through 3D fully automated image analysis. Scientific Reports, 2018, 8, 1854.	1.6	15
14	Reduced longitudinal contraction is associated with ischemic mitral regurgitation after posterior MI. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H322-H329.	1.5	6
15	Noninvasive Liver Assessment in Adult Patients With Fontan Circulation Using Acoustic Radiation Force Impulse Elastography and Hepatic Magnetic Resonance Imaging. World Journal for Pediatric & Samp; Congenital Heart Surgery, 2018, 9, 22-30.	0.3	10
16	Primary Effect of SERCA2a Gene Transfer on Conduction Reserve in Chronic Myocardial Infarction. Journal of the American Heart Association, 2018, 7, e009598.	1.6	16
17	Chronic Pulmonary Artery Embolization Models in Large Animals. Methods in Molecular Biology, 2018, 1816, 353-366.	0.4	1
18	Modeling Pulmonary Hypertension: A Pig Model of Postcapillary Pulmonary Hypertension. Methods in Molecular Biology, 2018, 1816, 367-383.	0.4	6

#	Article	IF	CITATIONS
19	Safety and longâ€term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-4.	0.8	18
20	Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery. Basic Research in Cardiology, 2017, 112, 17.	2.5	30
21	Intracoronary Administration of Allogeneic Adipose Tissue–Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	43
22	Inhaled Gene Transfer for Pulmonary Circulation. Methods in Molecular Biology, 2017, 1521, 339-349.	0.4	7
23	Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition After Myocardial Infarction. Circulation Research, 2017, 121, 439-450.	2.0	62
24	Activation of α _{1A} â€adrenoceptors desensitizes the rat aorta response to phenylephrine through a neuronal NOS pathway, a mechanism lost with ageing. British Journal of Pharmacology, 2017, 174, 2015-2030.	2.7	12
25	Proteomic footprint of myocardial ischemia/reperfusion injury: Longitudinal study of the at-risk and remote regions in the pig model. Scientific Reports, 2017, 7, 12343.	1.6	37
26	Dynamic Edematous Response of the Human Heart to Myocardial Infarction. Circulation, 2017, 136, 1288-1300.	1.6	107
27	Increased Afterload Following MyocardialÂInfarction Promotes Conduction-Dependent Arrhythmias ThatÂAre Unmasked by Hypokalemia. JACC Basic To Translational Science, 2017, 2, 258-269.	1.9	15
28	Atrial Infarction and Ischemic Mitral Regurgitation Contribute to Post-MI Remodeling of the Left Atrium. Journal of the American College of Cardiology, 2017, 70, 2878-2889.	1.2	30
29	Route TESI. Circulation Research, 2017, 120, 1055-1056.	2.0	2
30	Impact of the Timing of Metoprolol Administration During STEMI on InfarctÂSize and Ventricular Function. Journal of the American College of Cardiology, 2016, 67, 2093-2104.	1.2	84
31	Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 67, 2032-2046.	1.2	62
32	Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Heart Failure, 2016, 3, 293-298.	1.4	45
33	Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic Research in Cardiology, 2016, 111, 49.	2.5	36
34	Systolic flow displacement using 3D magnetic resonance imaging in an experimental model of ascending aorta aneurysm: impact of rheological factors. European Journal of Cardio-thoracic Surgery, 2016, 50, 685-692.	0.6	6
35	Fast T2 gradient-spin-echo (T2-GraSE) mapping for myocardial edema quantification: first in vivo validation in a porcine model of ischemia/reperfusion. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 92.	1.6	68
36	\hat{I}^2 2- and \hat{I}^2 1-Adrenoceptor Expression Exhibits a Common Regulatory Pattern With GRK2 and GRK5 in Human and Animal Models of Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2015, 66, 478-486.	0.8	12

#	Article	IF	CITATIONS
37	Association of Myocardial T1-Mapping CMR With Hemodynamics and RV Performance in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 76-82.	2.3	71
38	Reply to "Letter to the editor: Characterizing preclinical model of ischemic heart failure: difference between LAD and LCx infarctions― American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H365-H366.	1.5	1
39	Pathophysiology Underlying the BimodalÂEdema Phenomenon After Myocardial Ischemia/Reperfusion. Journal of the American College of Cardiology, 2015, 66, 816-828.	1.2	123
40	Increased Stiffness Is the Major Early Abnormality in a Pig Model of Severe Aortic Stenosis and Predisposes to Congestive Heart Failure in the Absence of Systolic Dysfunction. Journal of the American Heart Association, 2015, 4, .	1.6	49
41	Stem Cell Factor Gene Transfer Improves Cardiac Function After Myocardial Infarction in Swine. Circulation: Heart Failure, 2015, 8, 167-174.	1.6	33
42	Myocardial Edema After Ischemia/Reperfusion Is Not Stable andÂFollowsÂaÂBimodal Pattern. Journal of the American College of Cardiology, 2015, 65, 315-323.	1.2	185
43	Combination Proximal Pulmonary Artery Coiling and Distal Embolization Induces Chronic Elevations in Pulmonary Artery Pressure in Swine. PLoS ONE, 2015, 10, e0124526.	1.1	15
44	Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1478-H1486.	1.5	43
45	Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1204-H1215.	1.5	82
46	Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure. Molecular Therapy, 2014, 22, 2038-2045.	3.7	70
47	Swine Model of Chronic Postcapillary Pulmonary Hypertension with Right Ventricular Remodeling: Long-Term Characterization by Cardiac Catheterization, Magnetic Resonance, and Pathology. Journal of Cardiovascular Translational Research, 2014, 7, 494-506.	1.1	34
48	Percutaneous Approaches for Efficient Cardiac Gene Delivery. Journal of Cardiovascular Translational Research, 2013, 6, 649-659.	1.1	28
49	<i>SUMO-1</i> Gene Transfer Improves Cardiac Function in a Large-Animal Model of Heart Failure. Science Translational Medicine, 2013, 5, 211ra159.	5.8	96
50	Myocardial and lymphocytic expression of eNOS and nNOS before and after heart transplantation: Relationship to clinical status. Life Sciences, 2013, 93, 108-115.	2.0	5
51	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 877-884.	2.9	27
52	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	2.9	645
53	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523.	1.6	97
54	Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure ethiology and correlates to clinical variables. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H368-H376.	1.5	46

#	Article	IF	Citations
55	Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/d <i>t</i> _{max} complementary or redundant?. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1423-H1428.	1.5	49
56	Influence of Metabolic Syndrome on Development of Cardiac Allograft Vasculopathy in the Transplanted Heart. Transplantation, 2012, 93, 106-111.	0.5	20
57	Myocardial G Protein Receptor–Coupled Kinase Expression Correlates With Functional Parameters and Clinical Severity in Advanced Heart Failure. Journal of Cardiac Failure, 2012, 18, 53-61.	0.7	40
58	Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Therapy, 2012, 19, 670-677.	2.3	29
59	Corrigendum to "Inflammatory markers in stable heart failure and their relationship with functional class―Int J Cardiol 129 (2008) 388–393. International Journal of Cardiology, 2011, 146, 484.	0.8	0
60	Relationship Between Functional Capacity and Quality of Life in Heart Transplant Patients. Transplantation Proceedings, 2011, 43, 2251-2252.	0.3	16
61	A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation. Clinical Transplantation, 2011, 25, 606-613.	0.8	15
62	EUR <i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	2.9	340
63	Post–Heart Transplant Tumors: Chronology and Impact on Survival. Transplantation Proceedings, 2010, 42, 3201-3203.	0.3	7
64	Can We Accept Donors Who Have Suffered a Resuscitated Cardiac Arrest?. Transplantation Proceedings, 2010, 42, 3091-3092.	0.3	11
65	Preliminary Results of a Prospective Randomized Study of Cyclosporine Versus Tacrolimus in the Development of Cardiac Allograft Vasculopathy at 1 Year After Heart Transplantation. Transplantation Proceedings, 2010, 42, 3199-3200.	0.3	8
66	Clinical Predictors of Immunotolerance in Heart Transplantation. Transplantation Proceedings, 2010, 42, 3183-3185.	0.3	0
67	Lymphomas in Heart Transplant Recipients: Do Antivirals Protect Against the Neoplastic Effect of Anti-CD3 Monoclonal Antibody?. Transplantation Proceedings, 2010, 42, 3206-3207.	0.3	1
68	Valor pronÃ ³ stico de la tasa de filtraciÃ ³ n glomerular al año del trasplante cardiaco. Revista Espanola De Cardiologia, 2010, 63, 564-570.	0.6	7
69	What is the best biomarker for diagnosis of rejection in heart transplantation?. Clinical Transplantation, 2009, 23, 672-680.	0.8	28
70	Myocardial and Peripheral Lymphocytic Transcriptomic Dissociation of β-adrenoceptors and G Protein–coupled Receptor Kinases in Heart Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 1166-1171.	0.3	10
71	Progression of Renal Dysfunction in Cardiac Transplantation After the Introduction of Everolimus in the Immunosuppressive Regime. Transplantation, 2009, 87, 538-541.	0.5	22
72	Predictor factors for the development of arterial hypertension following heart transplantation. Clinical Transplantation, 2008, 22, 760-764.	0.8	11

#	Article	IF	CITATIONS
73	Infiltración miocárdica tras exéresis de schwannoma melanótico pulmonar. Revista Espanola De Cardiologia, 2008, 61, 194-195.	0.6	O
74	Prognostic Relationship Between Two Serial Determinations of B-type Natriuretic Peptide and Medium–Long-term Events in Heart Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 735-740.	0.3	11
75	Follow-up Study on the Utility of von Willebrand Factor Levels in the Diagnosis of Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2008, 27, 760-766.	0.3	23
76	Inflammatory markers in stable heart failure and their relationship with functional class. International Journal of Cardiology, 2008, 129, 388-393.	0.8	30
77	Support Program for Heart Transplant Patients: Initial Experience. Transplantation Proceedings, 2008, 40, 3039-3040.	0.3	4
78	Randomized Prospective Study of the Evolution of Renal Function Depending on the Anticalcineurin Used. Transplantation Proceedings, 2008, 40, 2906-2908.	0.3	1
79	Clinical Variables Associated With the Presence of Inflammatory Infiltrates in Patients With Dilated Cardiomyopathy Undergoing Heart Transplantation. Transplantation Proceedings, 2008, 40, 3017-3019.	0.3	9
80	Correlation Between Beta-Adrenoceptors and G-Protein-Coupled Receptor Kinases in Pretransplantation Heart Failure. Transplantation Proceedings, 2008, 40, 3014-3016.	0.3	11
81	Differences in Early Postoperative Complications in Elective and Emergency Heart Transplantation. Transplantation Proceedings, 2008, 40, 3041-3043.	0.3	11
82	Tolerance Profile of the Proliferation Signal Inhibitors Everolimus and Sirolimus in Heart Transplantation. Transplantation Proceedings, 2008, 40, 3034-3036.	0.3	30
83	Utility of Oral Valganciclovir for Cytomegalovirus Prophylaxis: Does It Improve Treatment Compliance?. Transplantation Proceedings, 2008, 40, 3063-3064.	0.3	4
84	Long-Term Immunosuppressive Therapy in Recurrent Giant Cell Myocarditis in the Transplanted Heart: A Case Report. Transplantation Proceedings, 2007, 39, 1718-1719.	0.3	2
85	Ezetimibe in Heart Transplantation: Initial Experience. Transplantation Proceedings, 2007, 39, 2389-2392.	0.3	12
86	Mortality After Heart-Lung Transplantation Experience in a Reference Center. Transplantation Proceedings, 2007, 39, 2360-2361.	0.3	4
87	Mortality After Heart Transplantation in Adults With Congenital Heart Disease: A Single-Center Experience. Transplantation Proceedings, 2007, 39, 2357-2359.	0.3	23
88	mTOR Inhibitors and Their Secondary Effects in Cardiac Trasplant Recipients: A Descriptive Study. Transplantation Proceedings, 2007, 39, 2365-2367.	0.3	15
89	Clinical and Hemodynamic Profile of Patients With Advanced Heart Failure Considered for Heart Transplantation. Transplantation Proceedings, 2007, 39, 2341-2343.	0.3	8
90	mTOR Inhibitors: Do They Help Preserve Renal Function?. Transplantation Proceedings, 2007, 39, 2135-2137.	0.3	27

#	Article	IF	CITATIONS
91	Impact of Smoking on Survival After Heart Transplantation. Transplantation Proceedings, 2007, 39, 2377-2378.	0.3	23
92	Differences in Clinical Profile and Survival After Heart Transplantation According to Prior Heart Disease. Transplantation Proceedings, 2007, 39, 2350-2352.	0.3	11
93	Analysis of the Impact of Donor Gender on Early Mortality. Transplantation Proceedings, 2007, 39, 2375-2376.	0.3	23
94	Course of Patients With Chronic Hepatitis C Virus Infection Undergoing Heart Transplantation. Transplantation Proceedings, 2007, 39, 2353-2354.	0.3	16
95	Prognostic Value of Brain Natriuretic Peptide in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2007, 26, 986-991.	0.3	24
96	Miocarditis de células gigantes y displasia arritmogénica ventricular derecha. Revista Espanola De Cardiologia, 2007, 60, 782-784.	0.6	2
97	Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clinical Transplantation, 2007, 22, 070806210014002-???.	0.8	8
98	Does Amiodarone Influence Early Mortality in Heart Transplantation?. Transplantation Proceedings, 2006, 38, 2537-2538.	0.3	15
99	Evolutional Changes in Maintenance Immunosuppression Following Heart Transplantation. Transplantation Proceedings, 2006, 38, 2553-2554.	0.3	4
100	Induction Therapy With Daclizumab in Heart Transplantationâ€"How Many Doses?. Transplantation Proceedings, 2006, 38, 2541-2543.	0.3	14
101	Do Cardiovascular Risk Factors Influence Cardiac Allograft Vasculopathy?. Transplantation Proceedings, 2006, 38, 2572-2574.	0.3	10
102	Influence of Immunosuppression Regimen on Heart Transplantation Survival. Transplantation Proceedings, 2006, 38, 2550-2552.	0.3	11
103	Variations in the Frequency and Type of Infections in Heart Transplantation According to the Immunosuppression Regimen. Transplantation Proceedings, 2006, 38, 2558-2559.	0.3	6